Concepedia

Paul Statkevich

PS

Statistics

Publications

76

Citations

5.8K

H-Index

38

Active since

1993

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

Bristol-Myers Squibb (United States)

The University of Texas MD Anderson Cancer Center

The University of Texas Health Science Center at San Antonio

Dana-Farber Cancer Institute

Paul Statkevich is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in medicine, pharmacology, and pharmacotherapy.

ORCID

Top concepts

Publications per year

1993–2024

76

Publications

76

Randomized Phase III Study of Temozolomide Versus Dacarbazine in the Treatment of Patients With Advanced Metastatic Malignant Melanoma

Mark R. Middleton, Jean‐Jacques Grob, Neil K. Aaronson et al. · Journal of Clinical Oncology · 2000 · 1.3K citations

Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules

Anthony W. Tolcher, Stanton L. Gerson, Christiane Geyer et al. · British Journal of Cancer · 2003 · 366 citations · Full text

, , +18

Clinical trial of a farnesyltransferase inhibitor in children with Hutchinson–Gilford progeria syndrome

Leslie B. Gordon, Monica E. Kleinman, David T. Miller et al. · Proceedings of the National Academy of Sciences · 2012 · 365 citations · Full text

Absorption, metabolism, and excretion of 14C-temozolomide following oral administration to patients with advanced cancer.

Sharyn D. Baker, Mark Wirth, Paul Statkevich et al. · PubMed · 1999 · 225 citations

, , +20

Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies

M. Brada, Ian Judson, Philip Beale et al. · British Journal of Cancer · 1999 · 207 citations · Full text

, , +16

1–5 of 76